Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $25.00. The company’s shares closed yesterday at $13.54.
According to TipRanks, Bednar is an analyst with an average return of -4.9% and a 40.76% success rate. Bednar covers the Healthcare sector, focusing on stocks such as Align Tech, Cooper Co, and DENTSPLY SIRONA.
In addition to Piper Sandler, NovoCure also received a Buy from Wells Fargo’s Larry Biegelsen in a report issued on January 8. However, on January 9, H.C. Wainwright maintained a Hold rating on NovoCure (NASDAQ: NVCR).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $96.45 and a one-year low of $10.87. Currently, NovoCure has an average volume of 1.37M.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCR in relation to earlier this year. Most recently, in November 2023, Cordova Ashley, the CFO of NVCR bought 17,968.00 shares for a total of $172,452.55.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NovoCure (NVCR) Company Description:
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Read More on NVCR:
